Clinical Trial Update: Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bintrafusp alfa plus chemotherapy in EGFR-mutant non-small cell lung cancer resistant to tyrosine kinase inhibitors; study terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bintrafusp alfa (bintrafusp alfa)
• Chemotherapy (chemotherapy)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-08-01